The Potential Health Benefits of the Consciousness Energy Treated Novel Test Formulation on Various Functional Enzyme Biomarkers

The study objective was to investigate the effect of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Shirley Theresa Holmlund, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in six different cells. The Biofield Energy Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 115.6% and 53.3% restoration of viable cells at 10 and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 101.1%, 829.8% and 698.9% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 97.9% and 69.7% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 67.4% (at 0.1 µg/mL), 80.4% (at 0.1 µg/mL) and 119.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively compared to the untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.6% and 82.5% in the BT-Med + UT-TI group at 25 and 63 µg/mL, respectively; while 123.9% at 10 µg/mL in the BT-Med + BT-TI group compared to untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 53.6% and 59% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to the untreated. Serotonin level was significantly increased by 85.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups at 0.1 µg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 245.9% and 211.5% at 10 and 50 µg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 µg/mL) in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs and brain functional enzymes biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, emphysema, chronic bronchitis, asthma, osteoporosis, cystic fibrosis, etc.